Cinobufotalin prevents bone loss induced by ovariectomy in mice through the BMPs/SMAD and Wnt/β-catenin signaling pathways

Abstract

Background: Osteoporosis is a chronic bone disease characterized by bone loss and decreased bone strength. However, current anti-resorptive drugs carry a risk of various complications. The deep learning-based efficacy prediction system (DLEPS) is a forecasting tool that can effectively compete in drug screening and prediction based on gene expression changes. This study aimed to explore the protective effect and potential mechanisms of cinobufotalin (CB), a traditional Chinese medicine (TCM), on bone loss.

Methods: DLEPS was employed for screening anti-osteoporotic agents according to gene profile changes in primary osteoporosis. Micro-CT, histological and morphological analysis were applied for the bone protective detection of CB, and the osteogenic differentiation/function in human bone marrow mesenchymal stem cells (hBMMSCs) were also investigated. The underlying mechanism was verified using qRT-PCR, Western blot (WB), immunofluorescence (IF), etc.

Results: A safe concentration (0.25 mg/kg in vivo, 0.05 μM in vitro) of CB could effectively preserve bone mass in estrogen deficiency-induced bone loss and promote osteogenic differentiation/function of hBMMSCs. Both BMPs/SMAD and Wnt/β-catenin signaling pathways participated in CB-induced osteogenic differentiation, further regulating the expression of osteogenesis-associated factors, and ultimately promoting osteogenesis.

Conclusion: Our study demonstrated that CB could significantly reverse estrogen deficiency-induced bone loss, further promoting osteogenic differentiation/function of hBMMSCs, with BMPs/SMAD and Wnt/β-catenin signaling pathways involved.

Keywords

BMPs/SMAD / bone loss / cinobufotalin / hBMMSCs / osteogenesis / osteoporosis / Wnt/β-catenin signaling pathways

References

[1] BouvardB, Annweiler C, LegrandE. Osteoporosis in older adults. Joint Bone Spine. 2021;88:105135.

[2] KanisJA, CooperC, RizzoliR, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis F. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30:3-44.

[3] TountaTS. Diagnosis of osteoporosis in dental patients. J Frailty Sarcopenia Falls. 2017;2:21-27.

[4] LangdahlB. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone. 2020;139:115516.

[5] KhoslaS, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5:898-907.

[6] AnastasilakisAD, ToulisKA, PolyzosSA, Anastasilakis CD, MakrasP. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag. 2012;8:295-306.

[7] NeerRM, ArnaudCD, ZanchettaJR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.

[8] BorbaVZ, ManasNC. The use of PTH in the treatment of osteoporosis. Arq Bras Endocrinol Metabol. 2010;54:213-219.

[9] MiB, XiongW, XuN, et al. Strontium-loaded titania nanotube arrays repress osteoclast differentiation through multiple signalling pathways: in vitro and in vivo studies. Sci Rep. 2017;7:2328.

[10] LangdahlBL, Libanati C, CrittendenDB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585-1594.

[11] YeY, WenY, ZhangZ, He S, BoX. Drug-target interaction prediction based on adversarial Bayesian personalized ranking. Biomed Res Int. 2021;2021:6690154.

[12] JahanI, SakibSA, AlamN, Majumder M, SharminS, RezaASMA. Pharmacological insights into Chukrasia velutina bark: Experimental and computer-aided approaches. Animal Model Exp Med. 2022;5(4):377-388.

[13] de Sousa LuisJA, BarrosRPC, de SousaNF, Muratov E, ScottiL, ScottiMT. Virtual screening of natural products database. Mini Rev Med Chem. 2021;21:2657-2730.

[14] ChenB, Harrison RF, PapadatosG, et al. Evaluation of machine-learning methods for ligand-based virtual screening. J Comput Aided Mol Des. 2007;21:53-62.

[15] LambJ, Crawford ED, PeckD, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929-1935.

[16] ZhuJ, WangJ, WangX, et al. Prediction of drug efficacy from transcriptional profiles with deep learning. Nat Biotechnol. 2021;39:1444-1452.

[17] HanY, LiX, ZhangY, Han Y, ChangF, DingJ. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8:886.

[18] AndrzejewskaA, Lukomska B, JanowskiM. Concise review: mesenchymal stem cells: from roots to boost. Stem Cells. 2019;37:855-864.

[19] ChenG, DengC, LiYP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012;8:272-288.

[20] WuM, ChenG, LiYP. TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016;4:16009.

[21] BaronR, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179-192.

[22] TezukaK, YasudaM, WatanabeN, et al. Stimulation of osteoblastic cell differentiation by notch. J Bone Miner Res. 2002;17:231-239.

[23] KomoriT. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem. 2006;99:1233-1239.

[24] XuJ, QianSS, ChenYG, Li DY, YanQ. Systematic review and meta-analysis of efficacy and safety of Huachansu in treating cancer-related pain. Zhongguo Zhong Yao Za Zhi. 2019;44:2627-2636.

[25] GuoN, MiaoY, SunM. Transcatheter hepatic arterial chemoembolization plus cinobufotalin injection adjuvant therapy for advanced hepatocellular carcinoma: a meta-analysis of 27 trials involving 2, 079 patients. Onco Targets Ther. 2018;11:8835-8853.

[26] HanY, MaR, CaoG, et al. Combined treatment of cinobufotalin and gefitinib exhibits potent efficacy against lung cancer. Evid Based Complement Alternat Med. 2021;2021:6612365.

[27] WangJ, ChangH, SuM, et al. The potential mechanisms of cinobufotalin treating colon adenocarcinoma by network pharmacology. Front Pharmacol. 2022;13:934729.

[28] ChenR, GuanZ, ZhongX, Zhang W, ZhangY. Network pharmacology prediction: the possible mechanisms of Cinobufotalin against osteosarcoma. Comput Math Methods Med. 2022;2022:3197402.

[29] BenischP, Schilling T, Klein-HitpassL, et al. The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One. 2012;7:e45142.

[30] RossouwJE, Anderson GL, PrenticeRL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.

[31] KhojastepourL, HasaniM, GhasemiM, Mehdizadeh AR, TajeripourF. Mandibular trabecular bone analysis using local binary pattern for osteoporosis diagnosis. J Biomed Phys Eng. 2019;9:81-88.

[32] LiuH, GuR, ZhuY, et al. D-mannose attenuates bone loss in mice via Treg cell proliferation and gut microbiota-dependent anti-inflammatory effects. Ther Adv Chronic Dis. 2020;11:2040622320912661.

[33] QinC. Deepen the understanding and communication of animal models and experimental medicine research studies. Animal Model Exp Med. 2021;12:1.

[34] XianY, SuY, LiangJ, et al. Oroxylin a reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. Biochem Pharmacol. 2021;193:114761.

[35] XueXH, XueJX, HuW, ShiFL, YangY. Nomilin targets the Keap1-Nrf2 signalling and ameliorates the development of osteoarthritis. J Cell Mol Med. 2020;24:8579-8588.

[36] de CastroMJ, de Lamas C, Sanchez-PintosP, Gonzalez-LamunoD, Couce ML. Bone status in patients with phenylketonuria: a systematic review. Nutrients. 2020;12:2154.

[37] ParkTJ, HongH, KimMS, Park JS, ChiWJ, KimSY. Prunetin 4’-O-phosphate, a novel compound, in RAW 264.7 macrophages exerts anti-inflammatory activity via suppression of MAP kinases and the NFκB pathway. Molecules. 2021;26:6841.

[38] JdidiH, Ghorbel Koubaa F, AoiadniN, ElleuchA, Makni-Ayadi F, El FekiA. Effect of Medicago sativa compared to 17beta-oestradiol on osteoporosis in ovariectomized mice. Arch Physiol Biochemistry. 2022;128:951-958.

[39] HadrichF, SayadiS. Apigetrin inhibits adipogenesis in 3T3-L1 cells by downregulating PPARgamma and CEBP-alpha. Lipids Health Dis. 2018;17:95.

[40] SaeediM, GoliF, MahdaviM, et al. Synthesis and biological investigation of some novel sulfonamide and amide derivatives containing coumarin moieties. Iran J Pharm Res. 2014;13:881-892.

[41] ZhaoBJ, WangJ, SongJ, et al. Beneficial effects of a flavonoid fraction of Herba Epimedii on bone metabolism in ovariectomized rats. Planta Med. 2016;82:322-329.

[42] FanQ, ZhaoB, WangC, et al. Subchronic toxicity studies of cortex dictamni extracts in mice and its potential hepatotoxicity mechanisms in vitro. Molecules. 2018;23:2486.

[43] EmonsJ, ChaginAS, SavendahlL, Karperien M, WitJM. Mechanisms of growth plate maturation and epiphyseal fusion. Horm Res Paediatrician. 2011;75:383-391.

[44] WheaterG, Elshahaly M, TuckSP, DattaHK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 2013;11:201.

[45] WattsNB, Bilezikian JP, CamachoPM, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(Suppl 3):1-37.

[46] IlyasT, JinH, SiddiqueMI, Lee SJ, KimH, ChuaL. DIANA: a deep learning-based paprika plant disease and pest phenotyping system with disease severity analysis. Front Plant Sci. 2022;13:983625.

[47] SinghA, Chakraborty S, HeZ, et al. Deep learning-based predictions of older adults’adherence to cognitive training to support training efficacy. Front Psychol. 2022;13:980778.

[48] HajjoR, SetolaV, RothBL, Tropsha A. Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers. J Med Chem. 2012;55:5704-5719.

[49] StokesJM, YangK, SwansonK, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180:688-702.e13.

[50] KaiS, LuJH, HuiPP, Zhao H. Pre-clinical evaluation of cinobufotalin as a potential anti-lung cancer agent. Biochem Biophys Res Commun. 2014;452:768-774.

[51] SunH, WangW, BaiM, LiuD. Cinobufotalin as an effective adjuvant therapy for advanced gastric cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther. 2019;12:3139-3160.

[52] EmamH, RefaatA, JawaidP, et al. Hyperthermia and radiation reduce the toxic side-effects of bufadienolides for cancer therapy. Oncol Lett. 2017;14:1035-1040.

[53] AbbasnezhadA, SalamiF, MohebbatiR. A review: Systematic research approach on toxicity model of liver and kidney in laboratory animals. Animal Model Exp. 2022;5:436-444.

[54] ChengL, ChenYZ, PengY, et al. Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells. Tumour Biol. 2015;36:5763-5771.

[55] MengH, ShenM, LiJ, et al. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis. Eur J Pharmacol. 2021;906:174280.

[56] KawaiT, Katagiri W, OsugiM, SugimuraY, HibiH, UedaM. Secretomes from bone marrow-derived mesenchymal stromal cells enhance periodontal tissue regeneration. Cytotherapy. 2015;17:369-381.

[57] KatagiriT, WatabeT. Bone morphogenetic proteins. Cold Spring Harb Perspect Biol. 2016;8:a021899.

[58] MiyazonoK, KamiyaY, MorikawaM. Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010;147:35-51.

[59] MaX, YangJ, LiuT, et al. Gukang capsule promotes fracture healing by activating BMP/SMAD and Wnt/beta-catenin signaling pathways. Evid Based Complement Alternat Med. 2020;2020:7184502.

[60] LiY, JinD, XieW, et al. PPAR-gamma and Wnt regulate the differentiation of MSCs into adipocytes and osteoblasts respectively. Curr Stem Cell Res Ther. 2018;13:185-192.

[61] VerkaarF, ZamanGJ. New avenues to target Wnt/beta-catenin signaling. Drug Discov Today. 2011;16:35-41.

RIGHTS & PERMISSIONS

2023 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.